Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy

BACKGROUND: Daratumumab-based combination therapies have shown high rates of complete response (CR) and minimal residual disease negativity in patients with multiple myeloma. However, daratumumab, an IgGκ monoclonal antibody, interferes with electrophoretic techniques making it difficult to reliably...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Chim Acta
Hlavní autoři: Eveillard, Marion, Korde, Neha, Ciardiello, Amanda, Diamond, Benjamin, Lesokhin, Alexander, Mailankody, Sham, Smith, Eric, Hassoun, Hani, Hultcrantz, Malin, Shah, Urvi, Lu, Sydney, Salcedo, Meghan, Werner, Kelly, Rispoli, Jenna, Mastey, Donna, Landgren, Ola, Thoren, Katie
Médium: Artigo
Jazyk:Inglês
Vydáno: 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7994191/
https://ncbi.nlm.nih.gov/pubmed/33545108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cca.2021.01.021
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky